Thorsten B.
- Country
- France
- Department
- Hématologie
Research Overview
- Evaluation of Blinatumomab, Isatuximab, and Ponatinib in Frontline Therapy for Adults with Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma
- Randomized Precision Medicine Trial of Venetoclax Combination Therapy in Relapsed/Refractory T‑Cell Acute Lymphoblastic Leukemia
- Phase 1 Study of Actinomycin D Combined with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 174 of 336 partner sites.
Specializations
Myeloid Disorders
Specializes in investigating treatments for myelodysplastic syndromes and acute myeloid leukemia, with particular focus on higher-risk variants and novel therapeutic combinations.
- RARA-positive AML treatment approaches
- Higher-risk MDS therapeutic strategies
- Chronic myelogenous leukemia management
Evaluates innovative treatment combinations including venetoclax, azacitidine, and targeted therapies for myeloid malignancies.
Lymphoid Malignancies
Focuses on advancing treatment options for lymphomas and acute lymphoblastic leukemia, particularly in adult populations.
- Diffuse Large B-cell Lymphoma innovations
- Follicular and Marginal Zone Lymphoma therapies
- Adult ALL treatment protocols
Investigates novel immunotherapeutic approaches and combination strategies for lymphoid disorders.
Plasma Cell Disorders
Conducts research in multiple myeloma treatment, with emphasis on elderly patient populations and novel therapeutic combinations.
- Newly diagnosed multiple myeloma treatments
- Relapsed/refractory myeloma strategies
- Minimal residual disease assessment
Studies innovative immunotherapy combinations and transplant-ineligible patient treatment approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.